Клиничен опит Inovelon е прилаган в едно двойно- сляпо, контролирано с плацебо проучване в дози до 45 mg/ kg/ ден в продължение на 84 дни на 139 пациента с недостатъчно контролирани гърчове, свързани със синдрома на Lennox- Gastaut (в т. ч. както атипични абсанси, така и гърчове с падане).
Clinical experience Inovelon was administered in a double blind, placebo-controlled study, at doses of up to 45 mg/ kg/ day for 84 days, to 139 patients with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (including both atypical absence seizures and drop attacks). Male or female patients (between 4 and 30 years of age) were included if they were being treated with 1 to 3 concomitant fixed-dose antiepileptic drugs.